The management team at AltheaDx has a proven record of success in clinical diagnostics. Meet our team.
Jorge Garces, Ph.D. President and Chief Executive Officer
Dr. Garces serves as CEO and President of AltheaDx and was co-founder of IDGenetix, Inc. prior to its acquisition by AltheaDx in May 2013. Jorge previously served as CEO and President of Enigma Diagnostics, Inc. and was also Vice President and Site Operations Manager at Hologic, Inc., where he led the development and submission to FDA for approval of their Cystic Fibrosis and HPV products. Additionally, Dr. Garces was a senior executive at GenMark Diagnostics and Third Wave Technologies. Earlier in his career, he held positions in major clinical diagnostic laboratories including Genzyme Genetics and Athena Diagnostics. Dr. Garces earned his doctorate in Cell and Molecular Biology from the City University of New York. He completed his post-doctoral training in neurobiology at the University of Massachusetts Medical School and received an MBA from the Kellogg Graduate School of Management at Northwestern University.
Andrew Jackson, Chief Financial Officer
Mr. Jackson joins us with over 20 years of finance experience. Prior to joining AltheaDx, Mr. Jackson was Chief Financial Officer and Principal Accounting Officer of Celladon Corporation, a publicly traded, clinical stage biotechnology company. During his time at Celladon, Mr. Jackson scaled the company through its growth and led Celladon’s public company compliance following its Initial Public Offering and completed the company’s accretive merger with Eiger Biopharmceuticals. Prior to Celladon, Mr. Jackson held senior finance positions at various life science and technology companies where he had extensive experience with mergers & acquisitions, treasury management, capital & debt financing and financial planning. He holds a B.S.B in Accounting from the University of Minnesota, an M.B.A in Finance from San Diego State University and is a Certified Public Accountant.
Joel Centeno, Senior Vice President Regulatory, Quality, and Clinical
Mr. Centeno has over 17 years experience in molecular diagnostics, medical devices and bio-implants. His expertise focuses primarily in global regulatory approvals, quality systems, clinical trials, ISO accreditations and FDA inspections. Prior to joining AltheaDx, Mr. Centeno served as Vice President Regulatory Affairs, Quality Assurance, and Clinical Affairs at GenMark Diagnostics and Vice President Regulatory Affairs and Quality Assurance at Enigma Diagnostics. Mr. Centeno has been responsible for the successful FDA approval of multiple in-vitro diagnostic tests in the area of infectious disease. Mr. Centeno’s professional career also includes leadership positions at Hologic, Inc., Boston Scientific and Tutogen Medical. Mr. Centeno received his B.S. in Materials Engineering and Metallurgy from the University of Florida in 1999 and is currently completing a M.S. degree in Quality Assurance from the Southern Polytechnic State University.
Andrew A. Lukowiak, Ph.D., Senior Vice President Operations and Head of Scientific Affairs
Dr. Lukowiak has served as the Senior Vice President of Operations and Head of Scientific Affairs for AltheaDx since its merger with IDgenetix® in 2013. Prior to joining AltheaDx, Dr. Lukowiak had held key positions at GenMark Diagnostics, Hologic, and Third Wave Technologies where he served as Assistant Vice President of R&D and played a central role in the development of the company’s IVD strategy; including the development of the first pharmacogenetic test to be cleared by the FDA for use with a specific drug. With over 15 years of experience in molecular diagnostics, Dr. Lukowiak has held management roles in the areas of R&D, Product Development, Operations, Software Development & Laboratory Automation, Project Management, Customer Service, and Billing. Dr. Lukowiak earned his doctorate in Genetics from the University of Georgia in Athens and his bachelor’s degree in Biology from Penn State University.